Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 10 2025
0mins
Should l Buy IMMP?
Source: NASDAQ.COM
Biotech Stock Movements: Several small- and mid-cap biotech stocks experienced significant gains in after-hours trading on September 9, 2025, driven by clinical updates, insider buying, and upcoming investor conferences, with notable performances from Immutep, Nautilus Biotechnology, and Pliant Therapeutics.
Immutep's Clinical Trial Update: Immutep's shares rose 4.37% after announcing that data from its Phase II trial for eftilagimod alpha will be presented at the CTOS 2025 conference, focusing on a rare cancer with high unmet need.
Nautilus Biotechnology Insider Buying: Nautilus Biotechnology's stock surged 12.25% following CEO Sujal M. Patel's significant insider purchases, indicating confidence in the company's future, alongside participation in an upcoming investor conference.
Kura Oncology's Regulatory Milestones: Kura Oncology's shares increased 6.12% after presenting at the H.C. Wainwright conference, highlighting key developments and upcoming regulatory milestones for its menin inhibitor targeting acute myeloid leukemia.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.451
Low
12.00
Averages
12.00
High
12.00
Current: 0.451
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Immutep is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline for contacting the firm set for July 6, 2026.
- False Statements Exposed: The complaint reveals that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company falsely claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages due to the company's misleading public statements, which significantly eroded investor trust and confidence in the company's future prospects.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit for potential recovery of losses, noting that the class has not yet been certified, meaning investors are not represented unless they take action to protect their rights.
See More
Immutep Limited Faces Class Action for Misleading Investors
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited, alleging that the company misled investors regarding the viability and efficacy of its drug candidate between March 24, 2025, and March 12, 2026, resulting in significant investor losses.
- Clinical Trial Issues: The Independent Data Monitoring Committee recommended discontinuation of Immutep's TACTI-004 clinical trial on March 13, 2026, due to failure to meet primary efficacy and safety endpoints, causing the ADR price to plummet from $2.76 to $0.48, an approximate 83% decline.
- Investor Impact: The concealment of internal clinical data and analyses regarding the TACTI-004 trial has left investors facing substantial financial losses, with the class action providing a means for affected shareholders to seek recovery, potentially impacting the company's reputation and future financing capabilities.
- Legal Consequences: Affected shareholders must submit their papers by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the importance of corporate governance and executive accountability, with Robbins LLP committed to assisting shareholders in recovering losses.
See More
Immutep Faces Class Action Lawsuit Over Alleged Misstatements
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep, alleging violations of federal securities laws from March 24, 2025, to March 12, 2026, seeking damages for affected investors.
- Allegations of Misstatements: The complaint asserts that Immutep misrepresented the status of its TACTI-004 trial, claiming strong operational progress while concealing critical data, which misled investors and could negatively impact stock prices.
- Investor Action Deadline: Affected investors have until July 6, 2026, to apply to be lead plaintiffs, highlighting the urgency for investors to act in light of potential recoveries from the lawsuit.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis and has successfully recovered hundreds of millions for investors nationwide, underscoring their expertise in securities fraud cases.
See More
Faruqi & Faruqi Investigates Immutep Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Immutep for potential claims related to investors who purchased securities between March 24, 2025, and March 12, 2026, aiming to assess possible legal actions.
- Investor Rights Reminder: The firm reminds investors that July 6, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Partner Josh Wilson encourages affected investors to reach out directly for consultations, ensuring they receive necessary legal support and information regarding their options.
- Expert Legal Support: As a leading national securities law firm, Faruq & Faruqi provides specialized legal services aimed at helping investors address potential losses and pursue their legal rights.
See More
Class Action Lawsuit Announced for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Immutep Ltd. (NASDAQ: IMMP) ADRs between March 24, 2025, and March 12, 2026, indicating potential investor losses during this period.
- Compensation Structure: Investors joining the class action may receive compensation without any out-of-pocket costs, demonstrating the law firm's commitment to protecting investor rights and providing legal support for affected parties.
- Lawsuit Context: The lawsuit alleges that Immutep concealed negative information regarding the TACTI-004 trial, resulting in investor losses when the truth emerged, highlighting the company's lack of transparency in clinical trial reporting.
- Legal Counsel Recommendation: Rosen Law Firm advises investors to select qualified counsel with a proven track record, emphasizing the importance of careful selection of legal representation to achieve the best outcomes in the class action.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Immutep for violating §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company falsely claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Immutep is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline for contacting the firm set for July 6, 2026.
- False Statements Exposed: The complaint reveals that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company falsely claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages due to the company's misleading public statements, which significantly eroded investor trust and confidence in the company's future prospects.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit for potential recovery of losses, noting that the class has not yet been certified, meaning investors are not represented unless they take action to protect their rights.
See More
Immutep Limited Faces Class Action for Misleading Investors
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited, alleging that the company misled investors regarding the viability and efficacy of its drug candidate between March 24, 2025, and March 12, 2026, resulting in significant investor losses.
- Clinical Trial Issues: The Independent Data Monitoring Committee recommended discontinuation of Immutep's TACTI-004 clinical trial on March 13, 2026, due to failure to meet primary efficacy and safety endpoints, causing the ADR price to plummet from $2.76 to $0.48, an approximate 83% decline.
- Investor Impact: The concealment of internal clinical data and analyses regarding the TACTI-004 trial has left investors facing substantial financial losses, with the class action providing a means for affected shareholders to seek recovery, potentially impacting the company's reputation and future financing capabilities.
- Legal Consequences: Affected shareholders must submit their papers by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the importance of corporate governance and executive accountability, with Robbins LLP committed to assisting shareholders in recovering losses.
See More
Immutep Faces Class Action Lawsuit Over Alleged Misstatements
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep, alleging violations of federal securities laws from March 24, 2025, to March 12, 2026, seeking damages for affected investors.
- Allegations of Misstatements: The complaint asserts that Immutep misrepresented the status of its TACTI-004 trial, claiming strong operational progress while concealing critical data, which misled investors and could negatively impact stock prices.
- Investor Action Deadline: Affected investors have until July 6, 2026, to apply to be lead plaintiffs, highlighting the urgency for investors to act in light of potential recoveries from the lawsuit.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis and has successfully recovered hundreds of millions for investors nationwide, underscoring their expertise in securities fraud cases.
See More
Faruqi & Faruqi Investigates Immutep Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Immutep for potential claims related to investors who purchased securities between March 24, 2025, and March 12, 2026, aiming to assess possible legal actions.
- Investor Rights Reminder: The firm reminds investors that July 6, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Partner Josh Wilson encourages affected investors to reach out directly for consultations, ensuring they receive necessary legal support and information regarding their options.
- Expert Legal Support: As a leading national securities law firm, Faruq & Faruqi provides specialized legal services aimed at helping investors address potential losses and pursue their legal rights.
See More
Class Action Lawsuit Announced for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Immutep Ltd. (NASDAQ: IMMP) ADRs between March 24, 2025, and March 12, 2026, indicating potential investor losses during this period.
- Compensation Structure: Investors joining the class action may receive compensation without any out-of-pocket costs, demonstrating the law firm's commitment to protecting investor rights and providing legal support for affected parties.
- Lawsuit Context: The lawsuit alleges that Immutep concealed negative information regarding the TACTI-004 trial, resulting in investor losses when the truth emerged, highlighting the company's lack of transparency in clinical trial reporting.
- Legal Counsel Recommendation: Rosen Law Firm advises investors to select qualified counsel with a proven track record, emphasizing the importance of careful selection of legal representation to achieve the best outcomes in the class action.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Immutep for violating §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company falsely claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
See More
